Tislelizumab plus chemotherapy for patients with EGFR -mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy.

Hua Zhong,Xueyan Zhang,Panwen Tian,Tianqing Chu,Qisen Guo,Xinmin Yu,Zhuang Yu,Yalun Li,Lijuan Chen,Jie Liu,Yan Zhang,Yan Guan,Xun Shi,Jing Wang,Yanqiu Zhao,Baohui Han

Journal for immunotherapy of cancer（2023）

引用 0|浏览22

暂无评分

摘要

The study met the primary endpoint for the TIS+chemo cohort. Tislelizumab plus chemotherapy is effective with an acceptable safety profile for -mutated non-squamous NSCLC after EGFR TKI failure.

查看译文

关键词

Non-Small Cell Lung Cancer, Immune Checkpoint Inhibitors, Drug Therapy, Combination

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要